PEGBIO CO-B(02565)

65.000+2.750+4.42%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- PEGBIO CO-B (02565) Completes Placement of 5.136 Million Shares
  Stock News · 12-22
  PEGBIO CO-B (02565) Completes Placement of 5.136 Million Shares
- PegBio Raises HK$300 Million Through Placement of New H Shares
  Reuters · 12-22
  PegBio Raises HK$300 Million Through Placement of New H Shares
- PegBio Cornerstone Investor to Continue Holding On To Shares
  MT Newswires Live · 12-15
  PegBio Cornerstone Investor to Continue Holding On To Shares
- Key Announcement Analysis: PEGBIO CO-B (02565) Extends Cornerstone Lock-up as "Reassurance" and Launches Fundraising as "Charge Forward"
  Stock News · 12-15
  Key Announcement Analysis: PEGBIO CO-B (02565) Extends Cornerstone Lock-up as "Reassurance" and Launches Fundraising as "Charge Forward"
- PEGBIO CO-B (02565) Plans 10% Discount Placement of 5.136 Million Shares to Raise Approximately HK$296 Million
  Stock News · 12-14
  PEGBIO CO-B (02565) Plans 10% Discount Placement of 5.136 Million Shares to Raise Approximately HK$296 Million
- 10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled
  Stock News · 12-03
  10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled
- PegBio (02565) Releases November 2025 Monthly Return on Share Capital Movements
  Bulletin Express · 12-03
  PegBio (02565) Releases November 2025 Monthly Return on Share Capital Movements
- PegBio Applies for Hong Kong-Listed Share Full Circulation
  MT Newswires Live · 11-28
  PegBio Applies for Hong Kong-Listed Share Full Circulation
- PEGBIO CO-B (02565) Files Application with CSRC for H Share Full Circulation Plan
  Stock News · 11-28
  PEGBIO CO-B (02565) Files Application with CSRC for H Share Full Circulation Plan
- PegBio (2565) Announces Filing for H Share Full Circulation
  Bulletin Express · 11-28
  PegBio (2565) Announces Filing for H Share Full Circulation
- PegBio Co., Ltd. (2565) Announces Voluntary Lock-Up Extension by Cornerstone Investor
  Bulletin Express · 11-26
  PegBio Co., Ltd. (2565) Announces Voluntary Lock-Up Extension by Cornerstone Investor
- PEGBIO CO-B (02565): Cornerstone Investor Voluntarily Extends Lock-Up Period
  Stock News · 11-26
  PEGBIO CO-B (02565): Cornerstone Investor Voluntarily Extends Lock-Up Period
- US September Nonfarm Payrolls Exceed Expectations, Third Rate Cut This Year Unlikely
  Stock News · 11-21
  US September Nonfarm Payrolls Exceed Expectations, Third Rate Cut This Year Unlikely
- PegBio Says China NMPA Approves NDA For PB-119
  Reuters · 11-20
  PegBio Says China NMPA Approves NDA For PB-119
- HK Stock Movement | PEGBIO CO-B (02565) Rises Over 5% as PB-119 Approval Accelerates Global Commercialization Strategy
  Stock News · 11-18
  HK Stock Movement | PEGBIO CO-B (02565) Rises Over 5% as PB-119 Approval Accelerates Global Commercialization Strategy
- BUZZ-China's PegBio hits new high on approval of new drug application
  Reuters · 11-17
  BUZZ-China's PegBio hits new high on approval of new drug application
- HK Stock Movement | PEGBIO CO-B (02565) Surges Nearly 15% at Open as Core Product PB-119 Receives NDA Approval
  Stock News · 11-17
  HK Stock Movement | PEGBIO CO-B (02565) Surges Nearly 15% at Open as Core Product PB-119 Receives NDA Approval
- BRIEF-PegBio Says China NMPA Approves NDA For PB-119
  Reuters · 11-14
  BRIEF-PegBio Says China NMPA Approves NDA For PB-119
- PegBio Co., Ltd. (2565) Announces NMPA Approval for PB-119
  Bulletin Express · 11-14
  PegBio Co., Ltd. (2565) Announces NMPA Approval for PB-119
- PEGBIO CO-B (02565): China NMPA Approves New Drug Application for PB-119
  Stock News · 11-14
  PEGBIO CO-B (02565): China NMPA Approves New Drug Application for PB-119
Company Profile
Company Name
PEGBIO CO-B
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.pegbio.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
PegBio Co Ltd is a China-based company principally engaged in the discovery and development of innovative therapies. The Company's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The Company's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The Company's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia).

1D
5D
Day
Week
Month

Loading ...

High

66.000

Open

61.400

Volume%

0.97

Low

61.400

62.250

T/O Rate

0.04%

To The Moon

PEGBIO CO-B(02565)

Company Profile

Most Discussed